meat without animals,

at any price

Problem statement

Growing animal cells in bioreactors to produce meat faces three interlocking barriers that no company has overcome despite more than $1.6 billion in venture funding in 2021–2022 alone (TechCrunch). Believer Meats ($390M raised, shut down December 2025), Meatable ($105M, shut down December 2025), and SCiFi Foods ($40M, shut down 2024) all encountered the same fundamental constraints: (1) serum-free cell culture media costs are prohibitive — just two growth factors, FGF-2 and TGF-beta, comprise over 96% of the cost of a representative serum-free medium at bench-scale pricing, and expert estimates put media at 55% to over 95% of the marginal cost of the product (Specht/GFI 2020); (2) mammalian cells are shear-sensitive and oxygen-demanding, limiting practical bioreactor volumes far below what food-industry economics require; and (3) cultured cells do not spontaneously form meat — converting cell mass into something with the taste, texture, and mouthfeel of animal muscle tissue remains unsolved.

Why this matters

Livestock production accounts for ~14.5% of human-induced greenhouse gas emissions (FAO 2013) and 80% of agricultural land use (Our World in Data). Cultivated meat was positioned as the most direct alternative — identical products without animal farming. Investment in cultivated meat companies topped $1.36 billion at the 2021 peak (GFI) before cratering to $144 million in 2024 and $73.9 million in 2025 (GFI / Net Zero Insights). Multiple companies have shut down (Believer Meats, Meatable, SCiFi Foods, New Age Eats — formerly New Age Meats, CellRev, Upstream Foods), and no product is sold at price parity with conventional meat anywhere in the world. If the fundamental barriers are not resolved, the cultivated meat pathway to sustainable protein is effectively closed.

What’s been tried and why it hasn’t worked

Believer Meats built a 200,000 sq ft factory in North Carolina with bioreactors at 50L, 200L, 2,000L, and 20,000L scales, but "the technology should never have been scaled the way it was, because it wasn't working at small scale" — cell growth without contamination events was not validated before scaling. SCiFi Foods hit real technical milestones — CRISPR-engineered beef cell lines growing in single-cell suspension in serum-free media, and a production run in a 500-liter bioreactor it claimed as an industry first — yet even with a hybrid product needing only ~10% cultivated cells, it reached the end of its runway in 2024 when it could not raise further capital. Meatable claimed to have slashed production times for cultivated pork by dramatically speeding up the process by which its pluripotent stem cells differentiate into fat and muscle, but folded in December 2025 after failing to secure the funding needed for its planned Singapore production facility — faster differentiation did not change the underlying scale-up economics. Industry-wide, pharmaceutical-grade bioreactors max out at ~20,000L for a reason: oxygen transfer, shear forces, and nutrient/waste gradients all worsen nonlinearly with volume.

What would unlock progress

Growth factor cost must decrease 100–1,000× through recombinant production optimization or identification of small-molecule substitutes that trigger the same signaling pathways. Novel bioreactor designs (hollow fiber, packed bed, or perfusion systems) that decouple cell density from reactor volume could circumvent the stirred-tank scaling ceiling. Tissue engineering approaches — scaffolds that guide cell organization into structured tissue — could bridge the "cells are not meat" gap. The most tractable near-term path may be hybrid products (small amounts of cultured cells blended with plant-based matrices) that reduce the required cell mass per serving.

Entry points for student teams

A team could screen small-molecule growth factor substitutes (e.g., agonists of FGF or TGF-beta receptors) in standard mammalian cell culture to identify cost-effective alternatives to recombinant proteins. A bioengineering team could prototype an alternative bioreactor geometry (hollow fiber or perfusion) and compare cell density and viability to stirred-tank baselines. Relevant disciplines: bioengineering, cell biology, food science, chemical engineering.